Indeed, the detection of LCN2 expression in clinical samples of CRC by immunohistochemistry indicated that the positive rate of LCN2 in primary tumors was significantly higher (66.5%, 266/400) than in lymph node metastases (31.2%, 42/135) (Fig. 1b). This evidence concerns the gene LCN2 and colorectal carcinoma.